Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

NCT03939624 · clinicaltrials.gov ↗

COMPLETED

Status

419734

Enrollment

OTHER

Sponsor class

Conditions

Type2 Diabetes
Myocardial Infarction
Ischemic Stroke
Cardiovascular Death
Heart Failure
All-Cause Mortality

Interventions

DRUG: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
DRUG: Dipeptidyl peptidase-4 (DPP-4) inhibitors

Sponsor

Canadian Network for Observational Drug Effect Studies, CNODES

Collaborators

[object Object]
[object Object]